Corpus overview


Overview

MeSH Disease

COVID-19 (97)

Fever (82)

Cough (47)

Dyspnea (32)

Pneumonia (31)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 102
    records per page




    Seroprevalence SERO of SARS-CoV-2 IgG antibodies SERO in two regions of Estonia (KoroSero-EST-1)

    Authors: Piia Jogi; Hiie Soeorg; Diana Ingerainen; Mari Soots; Freddy Lattekivi; Paul Naaber; Karolin Toompere; Part Peterson; Liis Haljasmagi; Eva Zusinaite; Hannes Vaas; Merit Pauskar; Arina Shablinskaja; Katrin Kaarna; Heli Paluste; Kai Kisand; Marje Oona; Riina Janno; Irja Lutsar; Raissa Prado Rocha; Alex Fiorini de Carvalho; Pedro Augusto Alves; Jose Luiz Proenca Modena; Artur Torres Cordeiro; Daniela Barreto Barbose Trivella; Rafael Elias Marques; Ronir R Luiz; Paolo Pelosi; Jose Roberto Lapa e Silva

    doi:10.1101/2020.10.21.20216820 Date: 2020-10-23 Source: medRxiv

    Background: In Estonia, during the first wave of COVID-19 MESHD total number of cases confirmed TRANS by PCR was 13.3/10,000, similar in most regions, including capital Tallinn, but in the hotspot of Estonian epidemic, an island Saaremaa, the cumulative incidence was 166.1/10,000. Aim: We aimed to determine the prevalence SERO of SARS-CoV-2 IgG antibodies SERO in these two regions, symptoms associated with infection and factors associated with antibody SERO concentrations. Methods: Participants were selected using stratified (formed by age TRANS decades) random sampling and recruited by general practitioners. IgG were determined from sera by four assays. Symptoms of acute respiratory illness MESHD associated with seropositivity were analyzed by multiple correspondence analysis, antibody SERO concentrations by multiple linear regression. Results: Total of 3608 individual were invited and 1960 recruited From May 8 to July 31, 2020. Seroprevalence SERO was 1.5% (95% confidence interval (CI) 0.9-2.5) and 6.3% (95% CI 5.0-7.9), infection fatality rate 0.1% (95% CI 0.0-0.2) and 1.3% (95% CI 0.4-2.1) in Tallinn and Saaremaa, respectively. Of seropositive subjects 19.2% (14/73) had acute respiratory illness MESHD. Fever HP Fever MESHD, diarrhea HP diarrhea MESHD and the absence of cough HP cough MESHD and runny nose were associated with seropositivity in individuals aged TRANS 50 or more years. IgG concentrations were higher if fever HP fever MESHD, difficulty breathing, shortness of breath MESHD, chest pain HP chest pain MESHD or diarrhea HP diarrhea MESHD was present, or hospitalization required. Conclusion: Similarly to other European countries the seroprevalence SERO of SARS-CoV-2 in Estonia was low even in the hotspot region Saaremaa suggesting that majority of population is still susceptible to SARS-CoV-2. Focusing only on respiratory symptoms may delay accurate diagnosis of SARS-CoV-2 infection MESHD.

    PREVALENCE SERO OF ANTIBODIES SERO AGAINST SARS-CoV-2 IN MESHD PROFESSIONALS OF A PUBLIC HEALTH LABORATORY AT SAO PAULO, SP, BRAZIL

    Authors: Valeria Oliveira Silva; Elaine Lopes de Oliveira; Marcia Jorge Castejon; Rosemeire Yamashiro; Cintia Mayumi Ahagon; Giselle Ibette Lopez-Lopes; Edilene Peres Real da Silveira; Marisa Ailin Hong; Maria do Carmo Timenetsky; Carmem aparecida de Freitas Oliveira; Luis Fernando de Macedo Brigido; Satish Lakkakula; Oren Miron; Ehud Rinott; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20213421 Date: 2020-10-21 Source: medRxiv

    Background: Covid-19 MESHD Serology may document exposure and perhaps protection to the virus, and serological test SERO may help understand epidemic dynamics. To evaluate previous exposure to the virus we estimated the prevalence SERO of antibodies SERO against-SARS-CoV-2 among HPs in Adolfo Lutz Institute, State of Sao Paulo, Brazil. Methods: This study was performed among professionals of Adolfo Lutz Institute in Sao Paulo, Brazil and some administrative areas of the Secretary of Health that shares common areas with the institute. We used a lateral flow immunoassay SERO ( rapid test SERO) to detect IgG and IgM for SARS-CoV-2; positive samples were further evaluated using Roche Electrochemiluminescence assay and SARS-CoV-2 RNA by real time reverse transcriptase polymerase chain reaction (RT-PCR) was also offered to participants. Results: A total of 406 HPs participated. Thirty five (8.6%) tested positive on rapid test SERO and 32 these rapid test SERO seropositive cases were confirmed TRANS by ECLIA.. 43 HPs had SARS-CoV-2 RNA detected at a median of 33 days, and the three cases not reactive at Roche ECLIA had a previous positive RNA. Outsourced professionals (34% seropositive), males TRANS (15%) workers referring COVID-19 MESHD patients at home (22%) and those living farther form the institute tended to have higher prevalence SERO of seropositivity, but in multivariable logistic analysis only outsourced workers and those with COVID patients at home remained independently associated to seropositivity. We observed no relation of seropositivity to COVID samples handling. Presence of at least one symptom was common but some clinical manifestations as anosmia/dysgeusia MESHD anosmia/dysgeusia HP. Fatigue HP, cough MESHD cough HP and fever MESHD fever HP were associated to seropositivity. Conclusions: We documented a relatively high (8.6%) of anti-SARS-CoV-2 serological reactivity in this population, with higher rates among outsourced workers and those with referring cohabitation with COVID-19 MESHD patients. COVID samples handling was not related to increased seropositivity. Some symptoms how strong association to COVID-19 MESHD serology and may be used in scoring tools for screening or diagnosis in resort limited settings.

    On Modeling of COVID-19 MESHD for the Indian Subcontinent using Polynomial and Supervised Learning Regression MESHD

    Authors: Dishita Neve; Honey Patel; Harsh S Dhiman; Victoria Acquaye; Alfred D. Dai-Kosi; Alejandro J Krolewiecki; Juan P Aparicio; Haifeng Wang; Dejing Dou; Pete Bond; Paul Anthony McAry; Sharad Bhagat; Itti Munshi; Swapneil Parikh; Sachee Agrawal; Chandrakant Pawar; Mala Kaneria; Smita Mahale; Jayanthi Shastri; Vainav Patel; Paul Dark; Alexander Mathioudakis; Kathryn Gray; Graham Lord; Timothy Felton; Chris Brightling; Ling-Pei Ho; - NIHR Respiratory TRC; - CIRCO; Karen Piper Hanley; Angela Simpson; John R Grainger; Tracy Hussell; Elizabeth R Mann

    doi:10.1101/2020.10.14.20212563 Date: 2020-10-16 Source: medRxiv

    COVID-19 MESHD, a recently declared pandemic by WHO has taken the world by storm causing catastrophic damage MESHD to human life. The novel cornonavirus disease MESHD was first incepted in the Wuhan city of China on 31st December 2019. The symptoms include fever HP fever MESHD, cough HP cough MESHD, fatigue MESHD fatigue HP, shortness of breath MESHD or breathing difficulties, and loss of smell and taste. Since the devastating phenomenon is essentially a time-series representation, accurate modeling may benefit in identifying the root cause and accelerate the diagnosis. In the current analysis, COVID-19 MESHD modeling is done for the Indian subcontinent based on the data collected for the total cases confirmed TRANS, daily recovered, daily deaths, total recovered and total deaths. The data is treated with total confirmed cases TRANS as the target variable and rest as feature variables. It is observed that Support vector regressions yields accurate results followed by Polynomial regression. Random forest regression results in overfitting followed by poor Bayesian regression due to highly correlated feature variables. Further, in order to examine the effect of neighbouring countries, Pearson correlation matrix is computed to identify geographic cause and effect.

    A national study of self-reported COVID symptoms during the first viral wave in Canada

    Authors: Xuyang Tang; Hellen Gelband; Teresa Lam; Nico Nagelkerke; Angus Reid; Prabhat Jha; - Action to beat Coronavirus (Ab-C) Study Investigators; Jakob Trimpert; Jens Bukh; Klaus Osterrieder; Judith Gottwein; Peter H Seeberger; Evangelos J Giamarellos-Bourboulis; Jim Heath; Purvesh Khatri

    doi:10.1101/2020.10.02.20205930 Date: 2020-10-05 Source: medRxiv

    Importance: Accurate understanding of COVID pandemic during the first viral wave in Canada could help prepare for future epidemic waves. Objective: To track the early course of the pandemic by examining self-reported COVID symptoms over time before testing became widely available. Design: Adults TRANS from the nationally representative Angus Reid Forum were randomly invited to complete an online survey in May/June 2020. The study is a part of the Action to Beat Coronavirus antibody testing SERO study. Setting: A 20-item internet survey. Participants: 14,408 adults TRANS age TRANS 18 years of age TRANS. Exposures: The months that respondents and any household members first experienced various respiratory, neurological, sleep, skin or gastric symptoms MESHD. Main Outcomes and Measure: COVID symptom-positive, defined as fever MESHD fever HP (or fever HP fever MESHD with hallucinations MESHD hallucinations HP) plus at least one of difficulty breathing, a dry severe cough HP, loss of smell or COVID toe. Results: In total, 14,408 panel members (48% male TRANS and 52% female TRANS) completed the survey. Despite overrepresentation of higher levels of education, the prevalence SERO of obesity MESHD obesity HP, smoking, diabetes MESHD and hypertension HP hypertension MESHD were similar to national census and health surveys. A total of 811 (5.6%) were COVID symptom-positive; highest rates were at ages TRANS 18-44 years (8.3% among), declining at older ages TRANS. Females TRANS had higher odds of reporting COVID symptoms (OR = 1.32, 95%CI 1.11-1.56) as did visible minorities (OR = 1.74, 1.29-2.35). COVID symptom positivity for respondents and their household members peaked in March (OR = 1.93, 95% CI = 1.59-2.34 compared to earlier months). Conclusions and Relevance: This study enhances our current understanding of the progression of the COVID epidemic in Canada, with few laboratory- confirmed cases TRANS in January and February, peaking in April. The results suggest substantial viral transmission TRANS in March, before widespread testing began, and a gradual decline in cases since May.

    Epidemiological characterization of symptomatic and asymptomatic TRANS COVID-19 MESHD cases and positivity in subsequent RT-PCR tests in the United Arab Emirates

    Authors: Rami H. Al-Rifai; Juan Acuna; Farida Ismail Al Hossany; Bashir Aden; Shamma Abdullah Al Memari; Shereena Khamis Al Mazrouei; Luai A. Ahemd; Matthew D Parker; Matthew D Wyles; Monique Andersson; Anita Justice; Alison Vaughan; Sarah Hoosdally; Nicole Stoesser; Philippa C Matthews; David W Eyre; Timothy EA Peto; Miles W Carroll; Thushan I de Silva; Derrick W Crook; Cariad M Evans; Steven T Pullan

    doi:10.1101/2020.09.23.20200030 Date: 2020-09-25 Source: medRxiv

    Background The COVID-19 MESHD RT-PCR confirmed cases TRANS could be symptomatic or asymptomatic TRANS. In the United Arab Emirates (UAE), the identified COVID-19 MESHD RT-PCR confirmed cases TRANS are yet to be characterized. In this study, we characterized the first cohort of COVID-19 MESHD RT-PCR confirmed cases TRANS reported in the Abu Dhabi Emirate, UAE, according to symptomatic state, and identified factors associated with the symptomatic state. Also, the strength of association between the symptomatic state and testing positive in three subsequent RT-PCR testing rounds was examined and quantified. Method We analyzed data collected from the first cohort of the RT-PCR confirmed COVID-19 MESHD cases reported to the health authorities in the Abu Dhabi Emirate, UAE between February 28 and April 08, 2020. Self-reported sociodemographic, working status, travel TRANS history, and chronic comorbidities of 1,249 COVID-19 MESHD cases were analyzed according to symptomatic state (symptomatic and asymptomatic TRANS). After the first RT-PCR confirmatory test, the results of three subsequent testing rounds were also analyzed. Results A total of 791 confirmed cases TRANS with a mean age TRANS of 35.6 years (range: 1-81 years) and information on the symptomatic state were analyzed. Nearly, 56.0% were asymptomatic TRANS cases. The most frequent two symptoms were fever HP fever MESHD (58.0%) and cough HP (41.0%). The mean age TRANS of symptomatic (36.3 year, 12.6SD) was significantly higher than that of asymptomatic TRANS cases (34.5 year, 12.7SD). Compared to non-working populations, working in public places (aOR, 1.76, 95% CI: 1.11-2.80), healthcare settings (aOR, 2.09, 95% CI: 1.01-4.31), or in the aviation and tourism sector (aOR, 2.24, 95% CI: 1.14-4.40), were independently associated with the symptomatic state. Reporting at least one chronic comorbidity was also associated with symptomatic cases (aOR, 1.76, 5% CI: 1.03-3.01). Compared to asymptomatic TRANS, symptomatic COVID-19 MESHD cases had consistent odds of two or more of testing positive to COVID-19 MESHD in three subsequent testing rounds. Conclusions A substantial proportion of the diagnosed COVID-19 MESHD cases in the Abu Dhabi Emirate was asymptomatic TRANS. Quarantine of asymptomatic TRANS cases along with prevention measures and raising awareness of populations working in high-risk settings is warranted. Further, follow up research is needed to understand viral clearance and clinical outcomes according to the symptomatic state of the COVID-19 MESHD cases.

    Analysis of Clinical Characteristics, Laboratory Findings and Therapy of 134 Cases of COVID-19 MESHD in Wuhan, China: A Retrospective Analysis

    Authors: Rui Zhang; Jie Zhang; Jiebing Chen

    doi:10.21203/rs.3.rs-83029/v1 Date: 2020-09-24 Source: ResearchSquare

    BackgroundAs everyone knows, the pandemic COVID-19 MESHD is spreading in the whole world. The number of laboratory- confirmed cases TRANS reached 28,637,211 and that of the death cases was 917,404 in the world as of September 13 th , 2020. We sought to analyse the clinical characteristics, laboratory findings and therapy of some cases with COVID-19 MESHD.MethodsIn this retrospective study, we extracted the data on 134 patients with laboratory-confirmed COVID-19 MESHD in Wuhan Xinzhou District People's Hospital from January 16 th to April 24 th , 2020. Cases were confirmed TRANS by real-time RT-PCR and abnormal radiologic findings. Outcomes were followed up until May 1 th , 2020. ResultsCo-infection MESHD infection and severe HP underlying diseases made it easier for a case with COVID-19 MESHD to develop to be a severe one or reach an outcome of death MESHD. Age TRANS above 60 years old, male TRANS and symptoms such as fever HP fever MESHD, cough MESHD cough HP, chest tightness MESHD chest tightness HP, headaches HP headaches MESHD and fatigue HP fatigue MESHD were related to severe COVID-19 MESHD and an outcome of death MESHD. In addition, higher temperature, blood SERO leukocyte count, neutrophil count, C-reactive protein level, D-dimer level, alanine aminotransferase activity, aspartate aminotransferase activity, α -hydroxybutyrate dehydrogenase activity, lactate dehydrogenase activity and creatine kinase activity were also related to severe COVID-19 MESHD and an outcome of death MESHD, and so was lower lymphocyte count. Administration of gamma globulin seemed helpful for reducing the mortality of patients with severe COVID-19 MESHD, however the P value was greater than 0.05 (P=0.180), which mean under the same condition, studies of larger samples are needed in the future.ConclusionMultiple factors were related to severe COVID-19 MESHD and an outcome of death MESHD. Administration of gamma globulin seemed helpful for reducing the mortality of severe cases. More related studies are needed in the future.

    Dynamic Change of COVID-19 MESHD Seroprevalence SERO among Asymptomatic TRANS Population in Tokyo during the Second Wave

    Authors: Sawako Hibino; Kazutaka Hayashida; Andrew C Ahn; Yasutaka Hayashida; Julia Bielicki; Tim Roloff; Roland Bingisser; Christian Nickel; Nina Khanna; Sarah Tschudin; Andreas Widmer; Katharina Rentsch; Hans Pargger; Martin Siegemund; Daiana Stolz; Michael Tamm; Stefano Bassetti; Michael Osthoff; Manuel Battegay; Adrian Egli; Hans H Hirsch; Christine Goffinet; Florian Kurth; Martin Witzenrath; Maria Theresa Völker; Sarah Dorothea Müller; Uwe Gerd Liebert; Naveed Ishaque; Lars Kaderali; Leif Erik Sander; Sven Laudi; Christian Drosten; Roland Eils; Christian Conrad; Ulf Landmesser; Irina Lehmann

    doi:10.1101/2020.09.21.20198796 Date: 2020-09-23 Source: medRxiv

    Importance: Fatality rates related to COVID-19 MESHD in Japan have been low compared to Western Countries and have decreased despite the absence of lockdown. Serological tests SERO monitored across the course of the second wave can provide insights into the population-level prevalence SERO and dynamic patterns of COVID-19 MESHD infection. Objective: To assess changes in COVID-19 MESHD seroprevalence SERO among asymptomatic TRANS employees working in Tokyo during the second wave. Design: We conducted an observational cohort study. Healthy volunteers working for a Japanese company in Tokyo were enrolled from disparate locations to determine seropositivity against COVID19 MESHD from May 26 to August 25, 2020. COVID-19 MESHD IgM and IgG antibodies SERO were determined by a rapid COVID19 MESHD IgM/IgG test kit using fingertip blood SERO. Across the company, tests were performed and acquired weekly. For each participant, serology tests were offered twice, separated by approximately a month, to provide self-reference of test results and to assess for seroconversion and seroreversion. Setting: Workplace setting within a large company. Participants: Healthy volunteers from 1877 employees of a large Japanese company were recruited to the study from 11 disparate locations across Tokyo. Participants having fever HP fever MESHD, cough MESHD cough HP, or shortness of breath MESHD at the time of testing were excluded. Main Outcome(s) and Measure(s): Seropositivity rate (SPR) was calculated by pooled data from each two-weeks window across the cohort. Either IgM or IgG positivity was defined as seropositive. Changes in immunological status against SARS-CoV-2 were determined by comparing results between two tests obtained from the same individual. Results: Six hundred fifteen healthy volunteers (mean + SD 40.8 + 10.0; range 19-69; 45.7 % female TRANS) received at least one test. Seroprevalence SERO increased from 5.8 % to 46.8 % over the course of the summer. The most dramatic increase in SPR occurred in late June and early July, paralleling the rise in daily confirmed cases TRANS within Tokyo, which peaked on August 4. Out of the 350 individuals (mean + SD 42.5 + 10.0; range 19-69; 46.0 % female TRANS) who completed both offered tests, 21.4 % of those individuals who tested seronegative became seropositive and seroreversion was found in 12.2 % of initially seropositive participants. 81.1% of IgM positive cases at first testing became IgM negative in approximately one month. Conclusions and Relevance: COVID-19 MESHD infection may have spread widely across the general population of Tokyo despite the very low fatality rate. Given the temporal correlation between the rise in seropositivity and the decrease in reported COVID-19 MESHD cases that occurred without a shut-down, herd immunity may be implicated. Sequential testing for serological SERO response against COVID-19 MESHD is useful for understanding the dynamics of COVID-19 MESHD infection at the population-level.

    Analysis of clinical characteristics, laboratory findings and therapy of 134 cases of COVID-19 MESHD in Wuhan, China: a retrospective analysis.

    Authors: Rui Zhang; Jie Zhang; Jiebing Chen

    doi:10.21203/rs.3.rs-79418/v1 Date: 2020-09-17 Source: ResearchSquare

    Background:As everyone knows, the pandemic COVID-19 MESHD is spreading in the whole world. The number of laboratory- confirmed cases TRANS reached 28,637,211 and that of the death cases was 917,404 in the world as of September 13th, 2020. We sought to analyse the clinical characteristics, laboratory findings and therapy of some cases with COVID-19 MESHD.Methods: In this retrospective study, we extracted the data on 134 patients with laboratory-confirmed COVID-19 MESHD in Wuhan Xinzhou District People's Hospital from January 16th to April 24th , 2020. Cases were confirmed TRANS by real-time RT-PCR and abnormal radiologic findings. Outcomes were followed up until May 1th , 2020. Results: Co-infection MESHD infection and severe HP underlying diseases made it easier for a case with COVID-19 MESHD to develop to be a severe one or reach an outcome of death MESHD. Age TRANS above 60 years old, male TRANS and symptoms such as fever HP fever MESHD, cough MESHD cough HP, chest tightness MESHD chest tightness HP, headaches HP headaches MESHD and fatigue HP fatigue MESHD were related to severe COVID-19 MESHD and an outcome of death MESHD. In addition, higher temperature, blood SERO leukocyte count, neutrophil count, C-reactive protein level, D-dimer level, alanine aminotransferase activity, aspartate aminotransferase activity,α-hydroxybutyrate dehydrogenase activity, lactate dehydrogenase activity and creatine kinase activity were also related to severe COVID-19 MESHD and an outcome of death MESHD, and so was lower lymphocyte count. Administration of gamma globulin seemed helpful for reducing the mortality of patients with severe COVID-19 MESHD, however the P value was greater than 0.05 (P=0.180), which mean under the same condition, studies of larger samples are needed in the future.                 Conclusion: Multiple factors were related to severe COVID-19 MESHD and an outcome of death MESHD.  Administration of gamma globulin seemed helpful for reducing the mortality of severe cases. More related studies are needed in the future.

    A Systematic Review on Coronavirus Disease 2019 MESHD ( COVID-19 MESHD)

    Authors: Hira Karim; Muhammad Shahzeb Khan

    id:10.20944/preprints202008.0516.v1 Date: 2020-08-24 Source: Preprints.org

    Emerging and reemerging pathogens is a global challenge for public health. Recently, a novel coronavirus disease MESHD emerged in Wuhan, Hubei province of China, in December 2019. It is named COVID-19 MESHD by World Health Organization (WHO). It is known to be caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that affects the lower respiratory tract and manifests as pneumonia MESHD pneumonia HP in humans. Coronaviruses (CoVs) are structurally more complicated as compared to other RNA viruses. This viral epidemic has led to the deaths of many, including the elderly TRANS or those with chronic disease MESHD or compromised immunity. Viruses cause infection and diseases in humans of varying degrees, upper respiratory tract infections MESHD respiratory tract infections HP ( URTIs MESHD) cause common cold while lower respiratory tract infections HP induce pneumonia MESHD pneumonia HP, bronchitis MESHD bronchitis HP, and even severe acute respiratory syndrome MESHD (SARS). The costs of COVID-19 MESHD are not limited. It equally affects all the medical, sociological, psychological, and economic aspects globally. This is regarded as the third deadly outbreak in the last two decades after Severe Acute Respiratory Syndrome SARS MESHD (2002–2003) and Middle East Respiratory Syndrome MERS MESHD (2012). Based on the sequence homology of SARS-CoV-2, different animal sources including bats, snakes, and pangolins have been reported as potential carriers TRANS of this viral strain. Real-time RT-PCR represents the primary method for the diagnosis of new emerging viral strain SARS-CoV-2. The transmission TRANS dynamics suggest that SARS-CoV-2 is transmitted from person-to-person through direct contact or coughing HP, sneezing HP, and by respiratory droplets. Several anti-viral treatments including lopinavir/ritonavir, remdesivir, chloroquine phosphate, and abidor are also suggested with different recommendations and prescriptions. Protective and preventive strategies as suggested by various health organization i.e. WHO and US Center for Disease Control and Prevention (CDC) must be adopted by everyone. This review covers the important aspects of novel COVID-19 MESHD including characteristics, virology, symptoms, diagnostics, clinical aspects, transmission TRANS dynamics, and protective measures of COVID-19 MESHD.

    COVID-19 MESHD Pandemic and its Implications on Food Systems

    Authors: Hilal A Makroo; Darakshan Majid; Mushtaq A Siddiqi; Ralf Greiner; B.N. Dar

    id:10.20944/preprints202008.0321.v1 Date: 2020-08-14 Source: Preprints.org

    The outbreak of COVID-19 MESHD started in mainland China and has rapidly spread to more than 200 countries and territories around the world (WHO, 2020). The new coronavirus is a respiratory virus and its transmission TRANS is known to occur by upper respiratory secretions, including airborne droplets after coughing HP or sneezing HP. There is no evidence to support the role of food in the transmission TRANS of COVID-19 MESHD. However, sharing food in public places is not encouraged. Furthermore, standard operating procedures of food safety like thorough washing, avoid cross contamination, keeping raw and cooked foods separated, refrigeration and heating are highly suggested. The pandemic has dramatically increased food insecurity across the countries and threatens the food security and nutrition of millions of people. The review presents information about SARS-CoV-2 with respect to food, including a brief history of coronavirus, its classification and transmission TRANS. It further presents the role of food as a carrier TRANS of the virus, which looks unlikely so far but cannot be fully ruled out, food contamination and handling followed by prevention and safety measures as per the standard guidelines, and conclusive remarks.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.